There is on-going development of generic EU CTD Dossier of Galantamine, tablets.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
Galantamine hydrobromide is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.
More details at http://www.rxlist.com/cgi/generic/reminyl.htm
|Pharma licensing||Out-licensing (offer)|